Antidote - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB504240708

Publication Date:

April 3, 2024

Pages:

113

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Retailing [2]

Consumer & Retail [3]

Description:

Antidote is agent that counters the effects of poison or over dosage by another drug. It helps in neutralizing the dangerous effects of a poison in body and has scientific approaches that have been taken to assess the therapeutic value of antidotes.
The global market for Antidote was estimated to be worth US$ 8408 million in 2023 and is forecast to a readjusted size of US$ 10440 million by 2030 with a CAGR of 3.1% during the forecast period 2024-2030
Global Antidote key players include Roche, Pfizer, Bayer, etc. Global top three manufacturers hold a share about 15%.
North America is the largest market, with a share about 35%, followed by Europe and China, both have a share about 50 percent.
In terms of product, Chemical Antidotes is the largest segment, with a share about 45%. And in terms of application, the largest application is Pesticide Poisoning, followed by Heavy Metal Poisoning.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antidote, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antidote by region & country, by Type, and by Application.
The Antidote market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidote.
麻豆原创 Segmentation
By Company
Roche
Pfizer
Bayer
Johnson & Johnson
Novartis
Eli Lilly
Teva
Boehringer Ingelheim
Mylan
Fresenius Kabi
Baxter
Furen Pharmaceutical
Segment by Type:
Chemical Antidotes
Physical Antidotes
Pharmacological Antidotes
Segment by Application
Pesticide Poisoning
Heavy Metal Poisoning
Animal Bites Poisoning
Cyanide Poisoning
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antidote manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antidote in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antidote in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Antidote Product Introduction
1.2 Global Antidote 麻豆原创 Size Forecast
1.3 Antidote 麻豆原创 Trends & Drivers
1.3.1 Antidote Industry Trends
1.3.2 Antidote 麻豆原创 Drivers & Opportunity
1.3.3 Antidote 麻豆原创 Challenges
1.3.4 Antidote 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antidote Players Revenue Ranking (2023)
2.2 Global Antidote Revenue by Company (2019-2024)
2.3 Key Companies Antidote Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antidote Product Offered
2.5 Key Companies Time to Begin Mass Production of Antidote
2.6 Antidote 麻豆原创 Competitive Analysis
2.6.1 Antidote 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Antidote Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidote as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemical Antidotes
3.1.2 Physical Antidotes
3.1.3 Pharmacological Antidotes
3.2 Global Antidote Sales Value by Type
3.2.1 Global Antidote Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Antidote Sales Value, by Type (2019-2030)
3.2.3 Global Antidote Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pesticide Poisoning
4.1.2 Heavy Metal Poisoning
4.1.3 Animal Bites Poisoning
4.1.4 Cyanide Poisoning
4.1.5 Others
4.2 Global Antidote Sales Value by Application
4.2.1 Global Antidote Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Antidote Sales Value, by Application (2019-2030)
4.2.3 Global Antidote Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Antidote Sales Value by Region
5.1.1 Global Antidote Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Antidote Sales Value by Region (2019-2024)
5.1.3 Global Antidote Sales Value by Region (2025-2030)
5.1.4 Global Antidote Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Antidote Sales Value, 2019-2030
5.2.2 North America Antidote Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Antidote Sales Value, 2019-2030
5.3.2 Europe Antidote Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Antidote Sales Value, 2019-2030
5.4.2 Asia Pacific Antidote Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Antidote Sales Value, 2019-2030
5.5.2 South America Antidote Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antidote Sales Value, 2019-2030
5.6.2 Middle East & Africa Antidote Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antidote Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Antidote Sales Value
6.3 United States
6.3.1 United States Antidote Sales Value, 2019-2030
6.3.2 United States Antidote Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Antidote Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Antidote Sales Value, 2019-2030
6.4.2 Europe Antidote Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Antidote Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Antidote Sales Value, 2019-2030
6.5.2 China Antidote Sales Value by Type (%), 2023 VS 2030
6.5.3 China Antidote Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Antidote Sales Value, 2019-2030
6.6.2 Japan Antidote Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Antidote Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Antidote Sales Value, 2019-2030
6.7.2 South Korea Antidote Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Antidote Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Antidote Sales Value, 2019-2030
6.8.2 Southeast Asia Antidote Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Antidote Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Antidote Sales Value, 2019-2030
6.9.2 India Antidote Sales Value by Type (%), 2023 VS 2030
6.9.3 India Antidote Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Antidote Products, Services and Solutions
7.1.4 Roche Antidote Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Pfizer
7.2.1 Pfizer Profile
7.2.2 Pfizer Main Business
7.2.3 Pfizer Antidote Products, Services and Solutions
7.2.4 Pfizer Antidote Revenue (US$ Million) & (2019-2024)
7.2.5 Pfizer Recent Developments
7.3 Bayer
7.3.1 Bayer Profile
7.3.2 Bayer Main Business
7.3.3 Bayer Antidote Products, Services and Solutions
7.3.4 Bayer Antidote Revenue (US$ Million) & (2019-2024)
7.3.5 Johnson & Johnson Recent Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Profile
7.4.2 Johnson & Johnson Main Business
7.4.3 Johnson & Johnson Antidote Products, Services and Solutions
7.4.4 Johnson & Johnson Antidote Revenue (US$ Million) & (2019-2024)
7.4.5 Johnson & Johnson Recent Developments
7.5 Novartis
7.5.1 Novartis Profile
7.5.2 Novartis Main Business
7.5.3 Novartis Antidote Products, Services and Solutions
7.5.4 Novartis Antidote Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis Recent Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Profile
7.6.2 Eli Lilly Main Business
7.6.3 Eli Lilly Antidote Products, Services and Solutions
7.6.4 Eli Lilly Antidote Revenue (US$ Million) & (2019-2024)
7.6.5 Eli Lilly Recent Developments
7.7 Teva
7.7.1 Teva Profile
7.7.2 Teva Main Business
7.7.3 Teva Antidote Products, Services and Solutions
7.7.4 Teva Antidote Revenue (US$ Million) & (2019-2024)
7.7.5 Teva Recent Developments
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Profile
7.8.2 Boehringer Ingelheim Main Business
7.8.3 Boehringer Ingelheim Antidote Products, Services and Solutions
7.8.4 Boehringer Ingelheim Antidote Revenue (US$ Million) & (2019-2024)
7.8.5 Boehringer Ingelheim Recent Developments
7.9 Mylan
7.9.1 Mylan Profile
7.9.2 Mylan Main Business
7.9.3 Mylan Antidote Products, Services and Solutions
7.9.4 Mylan Antidote Revenue (US$ Million) & (2019-2024)
7.9.5 Mylan Recent Developments
7.10 Fresenius Kabi
7.10.1 Fresenius Kabi Profile
7.10.2 Fresenius Kabi Main Business
7.10.3 Fresenius Kabi Antidote Products, Services and Solutions
7.10.4 Fresenius Kabi Antidote Revenue (US$ Million) & (2019-2024)
7.10.5 Fresenius Kabi Recent Developments
7.11 Baxter
7.11.1 Baxter Profile
7.11.2 Baxter Main Business
7.11.3 Baxter Antidote Products, Services and Solutions
7.11.4 Baxter Antidote Revenue (US$ Million) & (2019-2024)
7.11.5 Baxter Recent Developments
7.12 Furen Pharmaceutical
7.12.1 Furen Pharmaceutical Profile
7.12.2 Furen Pharmaceutical Main Business
7.12.3 Furen Pharmaceutical Antidote Products, Services and Solutions
7.12.4 Furen Pharmaceutical Antidote Revenue (US$ Million) & (2019-2024)
7.12.5 Furen Pharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Antidote Industrial Chain
8.2 Antidote Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antidote Sales Model
8.5.2 Sales Channel
8.5.3 Antidote Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Roche
Pfizer
Bayer
Johnson & Johnson
Novartis
Eli Lilly
Teva
Boehringer Ingelheim
Mylan
Fresenius Kabi
Baxter
Furen Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.